FDA Priority Review for Merck-Daiichi Lung Cancer ADC Underlines Oncology Pipeline Build

What happened

The FDA granted priority review to Merck and Daiichi Sankyo's Biologics License Application for ifinatamab deruxtecan, an ADC targeting extensive-stage small cell lung cancer, potentially expediting its approval. This aligns with Merck's strategy, as detailed in the DeepValue report, to construct a multi-asset revenue bridge ahead of Keytruda's 2028 loss of exclusivity through launches and partnerships. However, the report cautions that Merck's current $120.9 price already reflects confidence in such pipeline additions, with near-term earnings dominated by $14.8B in 2026 acquisition accounting charges from deals like Cidara and Terns. While priority review is a positive regulatory step, it does not immediately mitigate the earnings quality risks or the need for tangible progress in key drivers like WINREVAIR durability and KEYTRUDA QLEX adoption. Thus, this news reinforces Merck's diversification efforts but doesn't alter the fundamental wait-and-see stance recommended in the report.

Implication

For investors, the FDA's priority review reduces regulatory uncertainty for a potential new oncology product, which could contribute to long-term revenue if approved and integrated into Merck's portfolio. However, it does not address the immediate overhang from acquisition-related charges, which are expected to suppress reported earnings and necessitate careful scrutiny of non-GAAP reconciliations. The DeepValue report's base case implies that upside requires concrete evidence from established drivers like WINREVAIR's patient starts and KEYTRUDA QLEX adoption, rather than incremental pipeline news. Consequently, while this development is incrementally positive, it lacks the clarity on charge containment or launch metrics needed to justify a rating upgrade or earlier entry. Investors should maintain a cautious approach, awaiting Q2-Q3 2026 updates on Terns deal closure, WINREVAIR momentum, and adherence to FY2026 non-GAAP EPS guidance of $5.00-$5.15.

Thesis delta

The news of FDA priority review for ifinatamab deruxtecan slightly de-risks Merck's oncology pipeline expansion but does not shift the core investment thesis. The WAIT rating remains appropriate as key risks—earnings quality deterioration from acquisition charges and lack of evidence from existing launches—are unchanged by this regulatory milestone. No material change is warranted; the focus stays on operational execution and charge management in the coming quarters.